Physician profile
Carl Ferguson
NPI 1619068681
$10,558.41
in general payments reported to CMS, 2019-2025
26 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $7,902 · 2021: $351 · 2022: $489 · 2023: $343 · 2024: $721 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408 · Entertainment: $24.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,407.78 |
| Entertainment | $24.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,732.86 | 2019-2020 | |
| Amgen INC. | $512.55 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $356.66 | 2020-2025 | Trelegy Ellipta |
| Abbvie INC. | $345.67 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $310.60 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $271.52 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Impulse Dynamics (USA) INC. | $173.67 | 2024 | Optimizer |
| Lilly USA, LLC | $156.85 | 2020-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $123.28 | 2019-2022 | |
| Optinose US, INC. | $104.28 | 2021-2022 | |
| Pfizer INC. | $62.81 | 2019-2020 | |
| Abbott Laboratories | $54.73 | 2019-2025 | Proclaim |
| Idorsia Pharmaceuticals US INC | $50.35 | 2022-2023 | Quviviq |
| Braeburn INC. | $44.53 | 2024 | Brixadi |
| Antares Pharma, INC. | $39.95 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $27.71 | 2025 | Voquezna |
| Orexo US, INC. | $25.01 | 2019-2021 | |
| Optos, INC. | $24.46 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Merck Sharp & Dohme LLC | $22.66 | 2023 | Belsomra |
| Otsuka America Pharmaceutical, INC. | $20.72 | 2023 | Rexulti |
| Fidia Pharma USA INC. | $20.38 | 2024 | Hymovis |
| Medtronic USA, INC. | $19.48 | 2019 | |
| Shire North American Group INC | $18.19 | 2019 | |
| Inspire Medical Systems, INC. | $13.95 | 2024 | Inspire |
| Boston Scientific Corporation | $12.99 | 2020 | |
| Eisai INC. | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.